Core C - Meenhard HerlynThis Cell Biology Core has major resources available that are provided to the program project investigators,including melanocytes, keratinocytes, fibroblasts, endothelial cells, bone marrow-derived mesenchymal stemcells, melanoma cells, monoclonal antibodies to melanoma-associated antigens, adenoviral and lentiviralvectors for growth factors, adhesion molecules, and oncogenes.Three-dimensional cultures of normal human skin (skin equivalents, organotypic cultures of skin) with a'dermis' of fibroblasts embedded in collagen and an 'epidermis' of melanocytes/melanoma cells andkeratinocytes are generated and provided to the program investigators. This three-dimensional model issuperior to two- dimensional culture because it mimics the in vivo context for the melanocytes/melanomacells. For screening studies, the Core is providing a spheroid culture model that allows investigations onmelanoma cells intimately interacting with stromal cells.The Core provides to program members orthotopic in vivo models of melanoma growth. Due to the differentarchitectures between mouse and human skin, melanomas, including xenografted cells, cannot be grown inthe natural murine skin environment. Instead, the Core will first graft human skin onto immunodeficient mice.When the skin has healed, we will inject human melanoma cells intradermally, where growth and invasionoccurs in the same way as in patients' lesions. The Core is also providing the subcutaneous melanomagrowth model for standard experiments. Besides providing resources to the other projects, the Core will testcompounds developed in Projects 3 and 4 and initially selected in Project 1. The responsibility of the Core isin testing expanded number of cell lines, in quality control testing of compounds through the differentbiological assays and through Western blotting. The Core also trains investigators of the Program in alltumor biological assays. Overall, this Core will provide efficient and high quality service to all interestedlaboratories within this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA114046-01A2
Application #
7445511
Study Section
Special Emphasis Panel (ZCA1-GRB-P (J1))
Project Start
2008-04-01
Project End
2013-03-31
Budget Start
2008-04-01
Budget End
2009-04-30
Support Year
1
Fiscal Year
2008
Total Cost
$117,245
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Kaur, Amanpreet; Ecker, Brett L; Douglass, Stephen M et al. (2018) Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov :
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Nti, Akosua A; Serrano, Leona W; Sandhu, Harpal S et al. (2018) FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina :
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:

Showing the most recent 10 out of 144 publications